Meiji And Dong-A Start European Ustekinumab Trial

Dosing Of Phase I Subjects Underway

 
• By Aidan Fry
Meiji
Meiji Seika and partner Dong-A have started dosing in a Phase I study for biosimilar ustekinumab • Source: Shutterstock

More from Biosimilars

More from Products